To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06522919
Title Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer (CombiCoR-Vax)
Acronym CombiCoR-Vax
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l. RECRUITING Meldola Forlì Cesena 47014 Italy Details
Pia Fondazione di Culto e Religione Azienda Ospedaliera "Card.G.Panico" NOT_YET_RECRUITING Tricase Lecce 73039 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field